Skip to search formSkip to main contentSkip to account menu

AZD2171

Known as: AZD 2171, AZD-2171, AZD2171 Maleate 
An indole ether quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, AZD2171 binds to and inhibits all three… 
National Institutes of Health

Related topics

Related topics

4 relations
AZD5438Cediranib MaleateRecentin

Broader (1)

cediranib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
Jak1/2 inhibition suppresses STAT3 phosphorylation that is characteristic of many cancers. Activated STAT3 promotes the… 
Review
2008
Review
2008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced…
PURPOSE AZD2171 is a potent inhibitor of vascular endothelial growth factor receptors that showed broad antitumor activity in… 
2008
2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
5047 Background: Cediranib (AZD2171) is an oral highly potent, selective pan-VEGFR tyrosine kinase inhibitor expected to show… 
2008
2008
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.
2008
2008
Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer
5501 Background: Angiogenesis is important for ovarian cancer growth; blocking angiogenesis can lead to ovarian cancer regression… 
Highly Cited
2007
Highly Cited
2007
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts
The vascular endothelial growth factor-A (VEGF-A) signaling pathway, a key stimulant of solid tumor vascularization, is primarily… 
Review
2007
Review
2007
Molecular targeted therapies and chemotherapy in malignant gliomas
Purpose of review To review current developments in the field of chemotherapy and targeted treatment of high-grade glioma. Recent… 
2007
2007
Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Highly Cited
2006
Highly Cited
2006
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
The vascular endothelial growth factor receptor (VEGFR) tyrosine kinases are being explored as targets for antiangiogenic cancer… 
2005
2005
Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors
3030 Background: AZD2171 is a highly potent inhibitor of VEGF receptor-2 tyrosine kinase activity. This Phase I trial assessed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)